Summit Therapeutics plc Summit Therapeutics To Present At The Rodman & Renshaw 20th Annual Global Investment Conference
August 29 2018 - 6:00AM
UK Regulatory
TIDMSUMM
Summit Therapeutics plc
("Summit", or the "Company")
Summit Therapeutics to Present at the Rodman & Renshaw 20(th) Annual
Global Investment Conference
Oxford, UK, and Cambridge, MA, US, 29 August 2018 - Summit Therapeutics
plc (NASDAQ: SMMT, AIM: SUMM) announces that Mr Glyn Edwards, Chief
Executive Officer, will present on the Company's plans to advance its
new mechanism antibiotic pipeline at the Rodman & Renshaw 20(th) Annual
Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, 6
September 2018 at 11:15am EDT in New York City.
A live webcast of the presentation will be available in the Investors
section of the Company's website, www.summitplc.com. A replay of the
webcast will be available from the same location soon after the live
presentation.
About Summit Therapeutics
Summit Therapeutics is a leader in antibiotic innovation. Our new
mechanism antibiotics are designed to become the new standards of care
for the benefit of patients and create value for payors and healthcare
providers. We are currently developing new mechanism antibiotics for C.
difficile infection and gonorrhoea and are using our proprietary Discuva
Platform to expand our pipeline. For more information, visit
www.summitplc.com and follow us on Twitter @summitplc.
For more information, please contact:
Summit
Glyn Edwards / Richard Pye (UK office) Tel: 44 (0)1235 443 951
Erik Ostrowski / Michelle Avery (US office) +1 617 225 4455
Cairn Financial Advisers LLP (Nominated
Adviser) Tel: +44 (0)20 7213 0880
Liam Murray / Tony Rawlinson
N+1 Singer (Joint Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / Jen Boorer
Panmure Gordon (Joint Broker) Tel: +44 (0)20 7886 2500
Freddy Crossley, Corporate Finance
James Stearns, Corporate Broking
MSL Group (US) Tel: +1 617 684 6557
Jon Siegal Jon.siegal@mslgroup.com
Consilium Strategic Communications (UK) Tel: +44 (0)20 3709 5700
Mary-Jane Elliott / Jessica Hodgson summit@consilium-comms.com
/ Lindsey Neville
-END-
This announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the information
contained therein.
Source: Summit Therapeutics plc via Globenewswire
http://www.summitplc.com/
(END) Dow Jones Newswires
August 29, 2018 07:00 ET (11:00 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From Apr 2024 to May 2024
Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Summit Therapeutics Plc (London Stock Exchange): 0 recent articles
More Summit Ther News Articles